drugset / Trial / NCT05881486

Antiemetic Prophylaxis With Fosaprepitant and Ondansetron in Patients Undergoing Thoracic Surgery

NCT05881486 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this clinical trial is to compare the efficacy, safety and feasibility of intravenous Fosaprepitant and Ondansetron for the prevention of postoperative nausea and vomiting in thoracicsurgery patients. Participants will be randomized in a 1:1 ratio to the Fosaprepitant and Ondansetron group.The groups were analyzed and compared for frequency of vomiting in 24 h after surgery. In addition, we will further compare the occurrence of postoperative pulmonary complications, length of hospital stay, nutrition and quality of life after surgery in patients treated with different antiemetic prophylaxis.

Timeline

Start
2023-06
Primary completion
2023-06
Completion
2023-06

Outcome

Missed primary endpoint

paper The 24-hour incidence of PONV was 31.0% [36] in the fosaprepitant group and 41.0% [48] in the ondansetron group (OR, 0.76; 95% CI, 0.53 to 1.07; P=0.112). PMID 41836527 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Fosaprepitant Other / unclassified 150 mg Intravenous
Comparator Ondansetron Other / unclassified 8 mg Intravenous